97 related articles for article (PubMed ID: 1419306)
1. Adjuvant tamoxifen in postmenopausal patients with breast cancer and negative axillary lymph nodes.
Scholten C; Sevelda P; Kurz C; Salzer H; Kubista E; Staffen A; Czerwenka K; Spona J; Aiginger P; Zielinski CC
Eur J Cancer; 1992; 28A(12):2083. PubMed ID: 1419306
[No Abstract] [Full Text] [Related]
2. [Adjuvant hormonal therapy in lymph node-negative breast carcinoma patients in the postmenopause].
Kurz C; Scholten C; Zielinski C; Czerwenka K; Kubista E; Spona J; Sevelda P
Dtsch Med Wochenschr; 1992 Dec; 117(51-52):1943-6. PubMed ID: 1478168
[TBL] [Abstract][Full Text] [Related]
3. Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Querci della Rovere G; Benson JR
J Natl Cancer Inst; 2001 Sep; 93(18):1420; author reply 1421-2. PubMed ID: 11562396
[No Abstract] [Full Text] [Related]
4. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen approved for node-negative breast cancer patients.
Oncology (Williston Park); 1990 Aug; 4(8):15-6. PubMed ID: 2145007
[No Abstract] [Full Text] [Related]
6. Axillary lymph node metastases as the sole clinical site of occult breast carcinoma.
Dragoumis DM; Tsiftsoglou AP; Sikou AD; Assimaki AS
J Coll Physicians Surg Pak; 2008 Aug; 18(8):517-9. PubMed ID: 18798593
[TBL] [Abstract][Full Text] [Related]
7. [Early experiences of breast-conservation treatment without axillary dissection for breast cancer patients with clinically-negative axillary nodes].
Ogawa Y; Nishioka A; Inomata T; Terashima M; Hamada N; Yoshida S; Ogoshi S; Kumon M
Nihon Igaku Hoshasen Gakkai Zasshi; 1994 Nov; 54(13):1277-84. PubMed ID: 7610031
[No Abstract] [Full Text] [Related]
8. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.
Fisher BJ; Perera FE; Cooke AL; Opeitum A; Stitt L
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):117-23. PubMed ID: 9747828
[TBL] [Abstract][Full Text] [Related]
9. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection.
Dees EC; Shulman LN; Souba WW; Smith BL
Ann Surg; 1997 Sep; 226(3):279-86; discussion 286-7. PubMed ID: 9339934
[TBL] [Abstract][Full Text] [Related]
10. Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes.
Hoebers FJ; Borger JH; Hart AA; Peterse JL; Th EJ; Lebesque JV
Cancer; 2000 Apr; 88(7):1633-42. PubMed ID: 10738222
[TBL] [Abstract][Full Text] [Related]
11. [A case regarded as an occult breast cancer treated without mastectomy].
Kawashima T; Miyazawa Y; Sakata H; Matsubara H; Ryu M; Ochiai T
Gan To Kagaku Ryoho; 2005 Jun; 32(6):825-8. PubMed ID: 15984524
[TBL] [Abstract][Full Text] [Related]
12. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
Johansen J; Overgaard J; Overgaard M
Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
[TBL] [Abstract][Full Text] [Related]
13. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
Camoriano JK; Loprinzi CL; Ingle JN; Therneau TM; Krook JE; Veeder MH
J Clin Oncol; 1990 Aug; 8(8):1327-34. PubMed ID: 2199619
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present status of Danish Breast Cancer Cooperative Group trials.
Mouridsen HT; Andersen AP; Brincker H; Dombernowsky P; Rose C; Andersen KW
NCI Monogr; 1986; (1):115-8. PubMed ID: 3534583
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy for node-negative breast cancer: a proactive view.
Glick JH
Important Adv Oncol; 1990; ():183-97. PubMed ID: 2182518
[No Abstract] [Full Text] [Related]
16. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.
Lancet; 1987 Jul; 2(8552):171-5. PubMed ID: 2885637
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of elderly patients with operable breast cancer treated with surgery without axillary dissection plus adjuvant tamoxifen.
Martelli G; DePalo G; Rossi N; Coradini D; Boracchi P; Galante E; Vetrella G
Br J Cancer; 1995 Nov; 72(5):1251-5. PubMed ID: 7577477
[TBL] [Abstract][Full Text] [Related]
18. The role of adjuvant therapy in the management of node negative breast cancer.
Young V; O'Connell PR; Keane FB
Ir Med J; 1990 Mar; 83(1):34-5. PubMed ID: 2361839
[No Abstract] [Full Text] [Related]
19. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
